1.Correction: 2023 Korean Society of Echocardiography position paper for diagnosis and management of valvular heart disease, part I: aortic valve disease
Sun Hwa LEE ; Se Jung YOON ; Byung Joo SUN ; Hyue Mee KIM ; Hyung Yoon KIM ; Sahmin LEE ; Chi Young SHIM ; Eun Kyoung KIM ; Dong Hyuk CHO ; Jun Bean PARK ; Jeong Sook SEO ; Jung Woo SON ; In Cheol KIM ; Sang Hyun LEE ; Ran HEO ; Hyun Jung LEE ; Jae Hyeong PARK ; Jong Min SONG ; Sang Chol LEE ; Hyungseop KIM ; Duk Hyun KANG ; Jong Won HA ; Kye Hun KIM ;
Journal of Cardiovascular Imaging 2024;32(1):34-
2.Correction: 2023 Korean Society of Echocardiography position paper for diagnosis and management of valvular heart disease, part I: aortic valve disease
Sun Hwa LEE ; Se Jung YOON ; Byung Joo SUN ; Hyue Mee KIM ; Hyung Yoon KIM ; Sahmin LEE ; Chi Young SHIM ; Eun Kyoung KIM ; Dong Hyuk CHO ; Jun Bean PARK ; Jeong Sook SEO ; Jung Woo SON ; In Cheol KIM ; Sang Hyun LEE ; Ran HEO ; Hyun Jung LEE ; Jae Hyeong PARK ; Jong Min SONG ; Sang Chol LEE ; Hyungseop KIM ; Duk Hyun KANG ; Jong Won HA ; Kye Hun KIM ;
Journal of Cardiovascular Imaging 2024;32(1):34-
3.Correction: 2023 Korean Society of Echocardiography position paper for diagnosis and management of valvular heart disease, part I: aortic valve disease
Sun Hwa LEE ; Se Jung YOON ; Byung Joo SUN ; Hyue Mee KIM ; Hyung Yoon KIM ; Sahmin LEE ; Chi Young SHIM ; Eun Kyoung KIM ; Dong Hyuk CHO ; Jun Bean PARK ; Jeong Sook SEO ; Jung Woo SON ; In Cheol KIM ; Sang Hyun LEE ; Ran HEO ; Hyun Jung LEE ; Jae Hyeong PARK ; Jong Min SONG ; Sang Chol LEE ; Hyungseop KIM ; Duk Hyun KANG ; Jong Won HA ; Kye Hun KIM ;
Journal of Cardiovascular Imaging 2024;32(1):34-
4.SoUth Korean study to PrEvent cognitive impaiRment and protect BRAIN health through Multidomain interventions via facE-to-facE and video communication plaTforms in mild cognitive impairment (SUPERBRAIN-MEET): Protocol for a Multicenter Randomized Controlled Trial
Soo Hyun CHO ; Hae Jin KANG ; Yoo Kyoung PARK ; So Young MOON ; Chang Hyung HONG ; Hae Ri NA ; Hong-Sun SONG ; Muncheong CHOI ; Sooin JEONG ; Kyung Won PARK ; Hyun Sook KIM ; Buong-O CHUN ; Jiwoo JUNG ; Jee Hyang JEONG ; Seong Hye CHOI
Dementia and Neurocognitive Disorders 2024;23(1):30-43
Background:
and Purpose: The SoUth Korea study to PrEvent cognitive impaiRment and protect BRAIN health through lifestyle intervention (SUPERBRAIN) proved the feasibility of multidomain intervention for elderly people. One-quarter of the Korean population over 65 years of age has mild cognitive impairment (MCI). Digital health interventions may be costeffective and have fewer spatial constraints. We aim to examine the efficacy of a multidomain intervention through both face-to-face interactions and video communication platforms using a tablet personal computer (PC) application in MCI.
Methods:
Three hundred participants aged 60–85 years, with MCI and at least one modifiable dementia risk factor, will be recruited from 17 centers and randomly assigned in a 1:1 ratio to the multidomain intervention and the waiting-list control groups. Participants will receive the 24-week intervention through the tablet PC SUPERBRAIN application, which encompasses the following five elements: managing metabolic and vascular risk factors, cognitive training,physical exercise, nutritional guidance, and boosting motivation. Participants will attend the interventions at a facility every 1–2 weeks. They will also engage in one or two self-administered cognitive training sessions utilizing the tablet PC application at home each week. They will participate in twice or thrice weekly online exercise sessions at home via the ZOOM platform. The primary outcome will be the change in the total scale index score of the Repeatable Battery for the Assessment of Neuropsychological Status from baseline to study end.
Conclusions
This study will inform the effectiveness of a comprehensive multidomain intervention utilizing digital technologies in MCI.
5.2023 Korean Society of Echocardiography position paper for diagnosis and management of valvular heart disease, part I: aortic valve disease
Sun Hwa LEE ; Se‑Jung YOON ; Byung Joo SUN ; Hyue Mee KIM ; Hyung Yoon KIM ; Sahmin LEE ; Chi Young SHIM ; Eun Kyoung KIM ; Dong‑Hyuk CHO ; Jun‑Bean PARK ; Jeong‑Sook SEO ; Jung‑Woo SON ; In‑Cheol KIM ; Sang‑Hyun LEE ; Ran HEO ; Hyun‑Jung LEE ; Jae‑Hyeong PARK ; Jong‑Min SONG ; Sang‑Chol LEE ; Hyungseop KIM ; Duk‑Hyun KANG ; Jong‑Won HA ; Kye Hun KIM ;
Journal of Cardiovascular Imaging 2024;32(1):11-
This manuscript represents the official position of the Korean Society of Echocardiography on valvular heart diseases.This position paper focuses on the clinical management of valvular heart diseases with reference to the guidelines recently published by the American College of Cardiology/American Heart Association and the European Society of Cardiology. The committee tried to reflect the recently published results on the topic of valvular heart diseases and Korean data by a systematic literature search based on validity and relevance. In part I of this article, we will review and discuss the current position of aortic valve disease in Korea.
6.Difference in Baseline Antimicrobial Prescription Patterns of Hospitals According to Participation in the National Antimicrobial Monitoring and Feedback System in Korea
Jihye SHIN ; Ji Young PARK ; Jungmi CHAE ; Hyung-Sook KIM ; Song Mi MOON ; Eunjeong HEO ; Se Yoon PARK ; Dong Min SEO ; Ha-Jin CHUN ; Yong Chan KIM ; Myung Jin LEE ; Kyungmin HUH ; Hyo Jung PARK ; I Ji YUN ; Su Jin JEONG ; Jun Yong CHOI ; Dong-Sook KIM ; Bongyoung KIM ;
Journal of Korean Medical Science 2024;39(29):e216-
This study aimed to evaluate the differences in the baseline characteristics and patterns of antibiotic usage among hospitals based on their participation in the Korea National Antimicrobial Use Analysis System (KONAS). We obtained claims data from the National Health Insurance for inpatients admitted to all secondary- and tertiary-care hospitals between January 2020 and December 2021 in Korea. 15.9% (58/395) of hospitals were KONAS participants, among which the proportion of hospitals with > 900 beds (31.0% vs.2.6%, P < 0.001) and tertiary care (50.0% vs. 5.2%, P < 0.001) was higher than that among non-participants. The consumption of antibiotics targeting antimicrobial-resistant gram positive bacteria (33.7 vs. 27.1 days of therapy [DOT]/1,000 patient-days, P = 0.019) and antibiotics predominantly used for resistant gram-negative bacteria (4.8 vs. 3.7 DOT/1,000 patient-days, P = 0.034) was higher in KONAS-participating versus -non-participating hospitals. The current KONAS data do not fully represent all secondary- and tertiary-care hospitals in Korea; thus, the KONAS results should be interpreted with caution.
7.Erratum: Korean Practice Guidelines for Gastric Cancer 2022: An Evidencebased, Multidisciplinary Approach
Tae-Han KIM ; In-Ho KIM ; Seung Joo KANG ; Miyoung CHOI ; Baek-Hui KIM ; Bang Wool EOM ; Bum Jun KIM ; Byung-Hoon MIN ; Chang In CHOI ; Cheol Min SHIN ; Chung Hyun TAE ; Chung sik GONG ; Dong Jin KIM ; Arthur Eung-Hyuck CHO ; Eun Jeong GONG ; Geum Jong SONG ; Hyeon-Su IM ; Hye Seong AHN ; Hyun LIM ; Hyung-Don KIM ; Jae-Joon KIM ; Jeong Il YU ; Jeong Won LEE ; Ji Yeon PARK ; Jwa Hoon KIM ; Kyoung Doo SONG ; Minkyu JUNG ; Mi Ran JUNG ; Sang-Yong SON ; Shin-Hoo PARK ; Soo Jin KIM ; Sung Hak LEE ; Tae-Yong KIM ; Woo Kyun BAE ; Woong Sub KOOM ; Yeseob JEE ; Yoo Min KIM ; Yoonjin KWAK ; Young Suk PARK ; Hye Sook HAN ; Su Youn NAM ; Seong-Ho KONG
Journal of Gastric Cancer 2023;23(2):365-373
8.Validation and Reliability of the Cataract-related Visual Function Questionnaire (CVFQ)
Eun Jin KOH ; Jong Min LEE ; Dong Hui LIM ; Danbee KANG ; Juhee CHO ; Min Kyung SONG ; In Kwon CHUNG ; Hun Jin CHOI ; Ji Woong CHANG ; Jong Hyun LEE ; Tae Young CHUNG ; Young Sub EOM ; Yeoun Sook CHUN ; So Hyang CHUNG ; Eun Chul KIM ; Joon Young HYON ; Do Hyung LEE
Journal of the Korean Ophthalmological Society 2023;64(11):1030-1040
Purpose:
To evaluate the reliability and validity of the Cataract-related Visual Function Questionnaire (CVFQ).
Methods:
A prospective cross-sectional study of 141 cataract patients was conducted from March 2022 to June 2022. The questionnaire was created based on a literature review and advice from an expert panel. This study determined its construct validity, criterion validity, internal consistency, and test-retest reliability.
Results:
The CVFQ consists of 15 items distributed among five categories: overall visual quality, overall visual function, distance vision, near vision, and glare. In the exploratory factor analysis of validity, the first three principal components explained 77.8% of the variance. The p-values in the Spearman correlation test comparing the pre- and postoperative total CVFQ score and best-corrected visual acuity (BCVA) were 0.006 and 0.004, respectively. In the reliability analysis, Cronbach’s alpha was > 0.9 for internal consistency and the p-values of each subcategory were all significant in the analysis of test-retest reliability.
Conclusions
Our results indicate that the CVFQ is useful for measuring the visual quality and visual function of cataract patients in Korea.
9.COVID-19 Vaccine-Associated Pneumonitis in the Republic of Korea:A Nationwide Multicenter Survey
Hongseok YOO ; Song Yee KIM ; Moo Suk PARK ; Sung Hwan JEONG ; Sung-Woo PARK ; Hong Lyeol LEE ; Hyun-Kyung LEE ; Sei-Hoon YANG ; Yangjin JEGAL ; Jung-Wan YOO ; Jongmin LEE ; Hyung Koo KANG ; Sun Mi CHOI ; Jimyung PARK ; Young Whan KIM ; Jin Woo SONG ; Joo Hun PARK ; Won-Il CHOI ; Hye Sook CHOI ; Chul PARK ; Jeong-Woong PARK ; Man Pyo CHUNG
Journal of Korean Medical Science 2023;38(14):e106-
Background:
Recent reports have suggested that pneumonitis is a rare complication following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).However, its clinical features and outcomes are not well known. The aim of this study was to identify the clinical characteristics and outcomes of patients with vaccine-associated pneumonitis following vaccination against SARS-CoV-2.
Methods:
In this nationwide multicenter survey study, questionnaires were distributed to pulmonary physicians in referral hospitals. They were asked to report cases of development or exacerbation of interstitial lung disease (ILD) associated with the coronavirus disease 2019 vaccine. Vaccine-associated pneumonitis was defined as new pulmonary infiltrates documented on chest computed tomography within 4 weeks of vaccination and exclusion of other possible etiologies.
Results:
From the survey, 49 cases of vaccine-associated pneumonitis were identified between February 27 and October 30, 2021. After multidisciplinary discussion, 46 cases were analyzed. The median age was 66 years and 28 (61%) were male. The median interval between vaccination and respiratory symptoms was 5 days. There were 20 (43%), 17 (37%), and nine (19%) patients with newly identified pneumonitis, exacerbation of pre-diagnosed ILD, and undetermined pre-existing ILD, respectively. The administered vaccines were BNT162b2 and ChAdOx1 nCov-19/AZD1222 each in 21 patients followed by mRNA-1273 in three, and Ad26.COV2.S in one patient. Except for five patients with mild disease, 41 (89%) patients were treated with corticosteroid. Significant improvement was observed in 26 (57%) patients including four patients who did not receive treatment. However, ILD aggravated in 9 (20%) patients despite treatment. Mortality was observed in eight (17%) patients.
Conclusion
These results suggest pneumonitis as a potentially significant safety concern for vaccines against SARS-CoV-2. Clinical awareness and patient education are necessary for early recognition and prompt management. Additional research is warranted to identify the epidemiology and characterize the pathophysiology of vaccine-associated pneumonitis.
10.Evaluation of Vancomycin TDM Strategies: Prediction and Prevention of Kidney Injuries Based on Vancomycin TDM Results
Byungwook KIM ; Sejung HWANG ; Eunjeong HEO ; Hyung-sook KIM ; Jongtak JUNG ; Eu Suk KIM ; Hong Bin KIM ; Kyunghoon LEE ; Jeong Su PARK ; Junghan SONG ; Joon Hee LEE ; Jae-Yong CHUNG ; Kyoung-Ho SONG ; Seonghae YOON
Journal of Korean Medical Science 2023;38(14):e101-
The current guidelines for therapeutic drug monitoring (TDM) of vancomycin suggest a target 24-hour area under the curve (AUC 0-24 ) of 400 to 600 mg*h/L for serious methicillinresistant Staphylococcus aureus infections. In this study, the predictabilities of acute kidney injury (AKI) of various TDM target parameters, target levels, and sampling methods were evaluated in patients who underwent TDM from January 2020 to December 2020. The AUC 0-24 and trough values were calculated by both one- and two-point sampling methods, and were evaluated for the predictability of AKI. Among the AUC 0-24 cutoff comparisons, the threshold value of 500 mg*h/L in the two sampling methods was statistically significant (P = 0.042) when evaluated for the predictability of AKI. Analysis by an receiver operating characteristic curve estimated an AUC 0-24 cutoff value of 563.45 mg*h/L as a predictor of AKI, and was proposed as the upper limit of TDM target.

Result Analysis
Print
Save
E-mail